AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02836054 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar puncture (LP)
Study NCT02836054 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: brain MRI
Study NCT03828877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A ( Group Acupuncture)
Description: Group A; Acupunctur will be done with Pres Needle (0.22x1.5 mm).Acupuncture will be done points fo SP 6, LI 4 , ST 36 , LİV 3, LU 9 ,LU 7.
Study NCT04440930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White tea
Description: Mouthwash with white tea five to six times a day for nine weeks
Study NCT04440930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salt water with soda
Description: Mouthwash with salt water and soda eight to ten times a day for nine weeks
Study NCT00815347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bosentan
Description: Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
Study NCT00815347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
Study NCT03549988 — intervention group
Intervention type: OTHER
Intervention: Fecal Calprotectin (FC) measurements with IBDocTM
Description: Each IBDocTM kit measure one fecal calprotectin value. The IBDoc® is an in-vitro diagnostic immunoassay analyzed by a downloadable smartphone application (CalApp®). A patient is able to process their stool at home using a test cassette.~The IBDocTM test results are displayed in a light signal system as three titre categories; normal \<100 µg/g (green), 100-300 µg/g (yellow), >300 µg/g (high). Patients' results will be sent directly to the central research coordinator through the IBDoc® Web Portal. If the FC is >250 µg/g a second FC will be performed within 2 weeks. If this result is \<250 µg/g patients will continue to monitor their FC every 2 months. If the second result is >250 µg/g, the attending physician will review the patient either by telephone or in the office within 7 days.
Study NCT01554293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching Placebo, single dose
Study NCT01554293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBL 1427 capsules
Description: PBL 1427 capsules 20 mg and 150 mg, single dose
Study NCT01260207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVR group
Description: Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
Study NCT02014051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB C-1101
Description: SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.~The dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle.
Study NCT03669718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISA101b
Description: Every 3 weeks for a total of 3 times
Study NCT03669718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Every 3 weeks for up to 24 months
Study NCT03669718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cemiplimab
Description: Every 3 weeks for up to 24 months
Study NCT03669718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every 3 weeks for a total of 3 times
Study NCT02570334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV-infected children initiated antiretroviral treatment within the first 7 months of life
Description: All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
Study NCT00109876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation
Description: Undergo RFA
Study NCT03452241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
Study NCT03452241 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The participants only receive the materials about the harm of substance use.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
Study NCT01520194 — intervention group
Intervention type: OTHER
Intervention: women attending reproductive health clinics
Description: women visiting BEMFAM´s clinics from January 2012 until Narch 2013 filled a self-administered questionnaire based on psychometric scale developes by Zhu TC et al
Study NCT01520194 — intervention group
Intervention type: OTHER
Intervention: medical records
Description: medical chart review of patients assisted January 2009 to December 2010
Study NCT02271399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: 300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
Study NCT02271399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
Study NCT00866918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Given IV
Study NCT00866918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV
Study NCT00866918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00866918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT00866918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given orally
Study NCT00866918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given orally
Study NCT00866918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT00866918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Given orally
Study NCT04760197 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00511797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH T04740B
Description: Drospirenone 1mg/EE 20µg (ß-CDC)
Study NCT00511797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH T00186DF
Description: Drospirenone 3 mg/EE 20µg (ß-CDC)
Study NCT00511797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH T04740F
Description: Drospirenone 2 mg/EE 20µg (ß-CDC)
Study NCT00511797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03989583 — intervention group
Intervention type: OTHER
Intervention: Infrared thermography
Description: Temperature observation in foot and footwear in healthy children
Study NCT03128541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound spine
Description: A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
Study NCT01121913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl
Description: The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
Study NCT01121913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl
Description: The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
Study NCT01121913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl
Description: The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
Study NCT03230409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet written in the patient's/family mother tongue
Description: At baseline visit, the parents or carers of the children and/or the young patients themselves (in the case of adolescents >12 years of age), were given a leaflet including questions and answers about the most common doubts that people have about anti-TB treatment (what to do if you forget a dose, if you vomit, if you have stomach ache, etc.). The study nurse read and reviewed the leaflet with the family. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
Study NCT03230409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A follow-up telephone call
Description: A follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits. The parents and/or patient were informed about this. This call was made to reinforce the information, answer any questions that may have arisen and insist on the importance of proper follow-up.
Study NCT03230409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eidus-Hamilton Test
Description: E-H test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test. This test is a rapid, simple point-of-care method to detect urinary acetyl-isoniazid, the main metabolite of isoniazid, up to 12-24 hours following isoniazid administration and is used as a surrogate marker of treatment adherence. The test consists of placing 4 drops of a 10%potassium cyanide solution and 9 drops of a 10%chloramine solution in a test tube containing 4 drops of patient urine. The result is considered positive if a deep red color develops after 1 minute. If a pink color slowly appears,this indicates that there are only traces of the metabolite. If there is no change in color, the result is considered negative and suggests no recent isoniazid intake. The sensitivity and specificity of this test have been reported to be over 99%
Study NCT03230409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A written questionnaire
Description: The parents or carers of the children and/or the young patients themselves were asked to complete a written questionnaire about adherence to anti-TB treatment on all the follow-up visits, which was partially adapted from two validated questionnaires on adherence to chronic therapies (SMAQ compliance test, Svarstad et al., 1999; and Hermes test, Rodríguez-Chamorro et al., 2008).
Study NCT00056329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 1,000 international units twice daily for three years
Study NCT00056329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multivitamin
Description: once daily for three years
Study NCT00056329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin
Description: once daily for three years
Study NCT00056329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for three years
Study NCT04643964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrée: Cognitive skills
Description: In this condition, participants view a video-based intervention covering cognitive emotion regulation skills. This intervention asks participants to respond to questions and practice identifying and evaluating their own thoughts using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
Study NCT04643964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrée: Behavioral skills
Description: In this condition, participants view a video-based intervention covering behavioral emotion regulation skills. This intervention asks participants to respond to questions and practice scheduling activities that might give them a sense of pleasure or accomplishment using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to schedule and engage in behaviors in line with the intervention skills.
Study NCT00854152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Escalating repeating dose
Study NCT04237675 — intervention group
Intervention type: PROCEDURE
Intervention: surgery and anesthesia
Description: patients with MS who received general or regional anesthesia for a surgery or labor
Study NCT02413593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT02413593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT04643964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrée: Interpersonal skills
Description: In this condition, participants view a video-based intervention covering interpersonal emotion regulation skills. This intervention asks participants to respond to questions and practice communicating effectively using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
Study NCT04643964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sampler skills
Description: In this condition, participants view a video-based intervention covering three emotion regulation skills: cognitive, behavioral, and interpersonal skills. This intervention asks participants to respond to questions and practice using skills using intervention worksheets. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
Study NCT03207074 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry
Description: The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
Study NCT03631719 — intervention group
Intervention type: BIOLOGICAL
Intervention: Wolbachia-carrying Ae.aegypti mosquitoes
Description: Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).
Study NCT04104932 — intervention group
Intervention type: PROCEDURE
Intervention: Open reduction and internal fixation
Description: Open reduction and internal fixation
Study NCT00792506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to anticipated end of treatment (week 18). The patients had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
Study NCT03760328 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Upper Airway Stimulation
Description: hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway
Study NCT03760328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Airway Stimulation
Description: hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway
Study NCT01712308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Given SC
Study NCT01712308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT01323816 — intervention group
Intervention type: OTHER
Intervention: Medically directed care
Description: There is no research directed care. Patients are treated as medically indicated.
Study NCT01236950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils mouthrinse
Description: Commercial mouthrinse with manufacturer's use indication
Study NCT01236950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delmopinol mouthrinse
Description: Commercial mouthrinse with manufacturer's use indication
Study NCT02949908 — intervention group
Intervention type: DRUG
Intervention: Rebif
Description: Participants diagnosed with RRMS who had discontinued their oral or injectable first-line multiple sclerosis (MS) medication, and have been receiving subcutaneous Interferon beta-1a (IFNβ-1b) (Rebif) were observed during the study. Participants received Rebif in accordance with the licensed Summary of Product Characteristics label or currently approved specific country product information.
Study NCT02732405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK5172 /MK8742
Description: tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin
Study NCT02878421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electronic cigarette + 16mg nicotine & flavor
Description: comparison of different strengths of nicotine
Study NCT02878421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electronic cigarette + 0mg nicotine & flavor
Description: comparison of different strengths of nicotine
Study NCT02878421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco cigarette
Description: Participant to remain on traditional cigarettes for 28 days
Study NCT00001941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daclizumab
Study NCT03148717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Cytotec
Study NCT03148717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
Study NCT01185262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomida and Rituximab
Description: Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.~Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).~In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.~If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).~In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1.
Study NCT01100216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: 4 mg for 12 days
Study NCT01100216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stonewall Dissolvable Tobacco Pieces
Description: 5.6 mg nicotine pieces for 12 days
Study NCT01100216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Camel Snus Frost
Description: pouches, 6.2 mg nicotine, for 12 days
Study NCT01100216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skoal Wintergreen
Description: Used at baseline (Days 1 and 2, 5-11) and then at every 7 day wash-out period.
Study NCT02603926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Description: Allopregnanolone is an endogenous inhibitory pregnane neurosteroid. It is synthesized from progesterone, and is a potent positive allosteric modulator of the action of γ-aminobutyric acid at GABAA receptor. Subjects will receive up to 12 infusions in the study. Subjects will all begin with 2.0 mg dosage. If tolerated, the next infusion will be 4.0 mg, and if that is tolerated, the next infusion will be 6.0 mg. Subject infusions will remain stable at the highest dosage tolerated for the remainder of the study. Each infusion will consist of 2.0 mg, 4.0 mg, or 6.0 mg aliquots of the 0.5 mg/ml allopregnanolone in 6% sulfobutylether-β-cyclodextrin with 0.9% sodium chloride injection solution.